13 May 2021 07:00
13 May 2021
Diurnal Group plc
("Diurnal" or the "Company")
Correction: Director Dealings
This is a correction to the Director Dealings announcement published at 3:44 p.m. on 12 May 2021 (RNS number 4297Y) which has been amended with the correct total beneficial interests of Sam Williams, Interim Chairman and Richard Bungay, Chief Financial Officer each of 0.07% of the total voting rights.
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that further to the Capital Raising, details of which were announced on 21 April 2021 and Admission, the following Directors' dealings as part of the Subscription and Open Offer have completed:
Sam Williams, Interim Chairman, subscribed for 28,571 Ordinary Shares at a price of 70 pence per Ordinary Share.
Martin Whitaker, Chief Executive Officer, subscribed for a total of 10,000 Ordinary Shares at 70 pence per share, including 6,000 shares to be held in pension schemes for the beneficial interest of his dependent children.
Richard Bungay, Chief Financial Officer, subscribed for 7,143 Ordinary Shares at a price of 70 pence per Ordinary Share.
John Goddard, Non-Executive Director, subscribed for 28,571 Ordinary Shares at a price of 70 pence per Ordinary Share.
Following Admission, the total beneficial interest of Sam Williams is 113,819 Ordinary Shares, representing 0.07% of the total voting rights, Martin Whitaker and his connected parties is 603,823 Ordinary Shares, representing 0.36% of the total voting rights, the total beneficial interest of Richard Bungay is 114,252 Ordinary Shares, representing 0.07% of the total voting rights and the total beneficial interest of John Goddard is 228,674 Ordinary Shares, representing 0.14% of the total voting rights.
The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 21 April 2021 unless otherwise stated.
Details of the full notifications received by the Company are set out below:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Names
| Sam Williams Martin Whitaker and dependent children Richard Bungay John Goddard | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Interim Chairman Chief Executive Officer Chief Financial Officer Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
70p | 28,571 | ||||
70p | 10,000 | ||||
70p | 7,143 | ||||
70p | 28,571 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | n/a | ||||
- Price | |||||
e)
| Date of the transaction
| 11 May 2021 | |||
f)
| Place of the transaction
| XLON | |||
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker) | +44 (0)20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: Rupert Dearden | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
DNL.L (DNL)